Dr. Paul Stoffels, Vice Chairman of the Executive Committee and Scientific Director of Johnson & Johnson to retire effective December 31, 2021
NEW BRUNSWICK, NJ, 12 October 2021 / PRNewswire / – Johnson & Johnson (NYSE: JNJ) today announced that Paul Stoffels MD., currently Vice-Chairman of the Executive Committee and Scientific Director of Johnson & Johnson, will retire from the Company as of December 31, 2021.
As Vice Chairman of the Executive Committee and Scientific Director, Dr Stoffels led the company’s research and product pipeline teams across all industries to define the company-wide mandate to discover and to develop transformational healthcare solutions. Under his leadership, Johnson & Johnson revitalized its innovation pipeline and created one of the strongest portfolios in the industry. As a strong advocate for solving some of the world’s most difficult health challenges, Dr Stoffels has relentlessly focused on unleashing the power of science and research and development innovation ( R&D) internal and external innovation to develop medicines and solutions for people all over the world. world.
“It has been an honor and privilege to lead Johnson & Johnson’s innovation agenda and to propel transformational innovation to deliver years of life and quality of life to millions of people around the world,” said the Dr Stoffels. “As a physician and scientist, it is gratifying to see the healthcare landscape transform as we unlock the best science and technology to deliver innovative medicines to solve the world’s most difficult health problems. As I reflect on the work of our talented and dedicated teams around the world, I am proud of the impact we have had and confident that our vibrant community of world-renowned scientists and engineers will position our company for continued success. . “
Committed to driving innovation and collaborating on the best science and technology, Dr Stoffels has created Johnson & Johnson Innovation – a vast network of innovation hotspots across the world – as a critical source to access to the best sciences and technologies thanks to strategic partnerships, licenses, acquisitions, incubation and investments. Today there are over 700 incubating companies in the JLABS ecosystem, countless strategic partnerships through Innovation Centers and many significant strategic investments through Johnson & Johnson Innovation – JJDC, Inc., the strategic arm. Johnson & Johnson venture capital fund.
“Paul is an exceptional human being, inspiring people every day. His remarkable ability to bring a vision and mission to life, and his commitment to improving and saving lives on a global scale, have moved the organization forward and generated enormous impact on global health and on the trajectory of Johnson & Johnson, ”said Alex gorsky, currently President and CEO of Johnson & Johnson. “Working with Johnson & Johnson’s senior R&D managers on the R&D Management Committee, Paul created a culture of people development, sponsorship, entrepreneurial leadership, developing generations of talented new leaders for Johnson & Johnson. Johnson. “
Previously, in his role as Global President of Pharmaceuticals, Dr Stoffels led the transformation of the pharmaceutical research and development pipeline for the Janssen Pharmaceutical Companies of Johnson & Johnson, resulting in a fundamental shift in the R&D paradigm that is now a model in the industry for productivity and innovation. Paul has also played a key role in numerous collaborations with external partners, including the licensing of key drugs, as well as the acquisition of Crucell and Actelion.
“With Paul at the helm, Janssen has rejuvenated its pipeline, launching several new drugs, making a difference for people around the world,” said Joaquin duato, vice chairman of the executive committee and next CEO of Johnson & Johnson from January 3, 2022. “Under Paul’s leadership, Janssen’s R&D teams have developed more than 25 new drugs in several therapeutic areas. Seven of these drugs have been added to the World Health Organization’s Essential Medicines List, a recognition of the tremendous impact these drugs are having on patients globally. ”
Dr Stoffels is a recognized global leader in the world of public health. By relentlessly focusing on treating and eliminating HIV, tuberculosis and Ebola, the world’s most devastating infections, his teams have developed drugs and vaccines. He founded Johnson & Johnson Global Public Health with a mission to make a difference for people in low- and middle-income countries. In 2020, he led the development of Johnson & Johnson’s single injection COVID-19 vaccine in record time. The vaccine is an essential tool in the fight against the pandemic for people living in low-income countries.
Paul is also a leading thought leader in the global public health arena, advancing key global health policy goals by representing Johnson & Johnson to organizations such as the Bill & Melinda Gates Foundation, the National Institutes of Health, the Innovative Medicines Initiative of the European Commission and World Health Organization. Paul was instrumental in founding TransCelerate Biopharma Inc., the Dementia Discovery Fund and other pre-competitive collaborations aimed at fueling investments in innovation and accelerating solutions for patients.
“I look forward to working with Alex and Joaquin to ensure a smooth transition for our R&D and innovation teams,” said Stoffels. “With vi years of life and quality of life for people around the world.”
On Paul Stoffels, MD
Paul studied medicine at the University of Diepenbeek and the University of Antwerp in Belgium and infectious diseases and tropical medicine at the Institute of Tropical Medicine in Antwerp, Belgium.
Paul began his career as a physician in Africa, focusing on clinical research in HIV and tropical diseases, and worked at Janssen Pharmaceutica under the tutelage of Dr. Paul Janssen in the early 1990s. He joined Johnson & Johnson in 2002 with the acquisition of Virco and Tibotec, where he led the development of several breakthrough products for the treatment of HIV that have helped turn this devastating and deadly disease into one. chronic and treatable disease.
About Johnson & Johnson
At Johnson & Johnson, we believe that good health is the foundation for vibrant lives, thriving communities and progress into the future. That’s why, for more than 130 years, we’ve strived to keep people healthy at all ages and at all stages of life. Today, as the world’s largest and most widely used healthcare company, we’re committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and make a healthy mind, body and environment available to everyone, everywhere. We combine our heart, our science and our ingenuity to profoundly change the trajectory of human health.
Cautions Regarding Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 concerning, among other things, future operational and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If the underlying assumptions prove to be incorrect or if known or unknown risks or uncertainties materialize, actual results could differ materially from Johnson & Johnson’s expectations and projections. Risks and uncertainties include, but are not limited to: risks related to the impact of the global COVID-19 pandemic, such as the extent and duration of the outbreak, government actions and restrictive measures implemented. work in response, significant delays and cancellations of medical procedures, supply chain disruptions and other impacts on the business, or on the Company’s ability to execute business continuity plans, due to from the COVID-19 pandemic, from economic factors, such as fluctuations in interest rates and exchange rates; competition, including technological advances, new products and patents obtained by competitors; challenges inherent in the research and development of new products, including the uncertainty of clinical success and obtaining regulatory approvals; the uncertainty of the commercial success of new and existing products; patent challenges; the impact of patent expirations; the Company’s ability to successfully execute its strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety issues resulting in product recalls or regulatory action; material adverse litigation or government actions, including related to product liability claims; changes in applicable laws and regulations, including tax laws and global healthcare reforms; trends towards containing health care costs; changes in the behavior and spending patterns of buyers of health care products and services; the financial instability of economies and international legal systems and sovereign risk; increased oversight of the health care sector by government agencies. A list and additional descriptions of these risks, uncertainties and other factors are available in Johnson & Johnson’s annual report on Form 10-K for the year ended. January 3, 2021 including in the sections entitled “Caution Regarding Forward-Looking Statements” and “Section 1A. Risk Factors ”in the Company’s latest Quarterly Report on Form 10-Q and subsequent Company filings with the Securities and Exchange Commission. Copies of these documents are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statements made in this press release speak only as of the date of this press release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
SOURCE Johnson & Johnson